Single-Centre, Randomised, Double-Blind, 3-Period Cross-Over Study to Investigate Effects on QTcF Interval of Verinurad ER 24 mg or IR 40 mg in Combination With Allopurinol 300 mg, Compared to Matching Placebos In Healthy Volunteers
Latest Information Update: 15 Dec 2022
At a glance
Most Recent Events
- 12 Dec 2022 Results assessing the the risk of QT prolongation for verinurad when combined with allopurinol published in the British Journal of Clinical Pharmacology
- 04 Sep 2020 Status changed from recruiting to completed.
- 31 Jul 2020 Planned End Date changed from 15 Sep 2020 to 27 Aug 2020.